|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 403.55 INR | +1.64% |
|
-3.50% | +2.45% |
| 07-09 | Biocon Limited Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili, A Biosimilar to Eylea | CI |
| 07-09 | Novo Nordisk launches weekly insulin shot Awiqli in India | RE |
| Market Cap | 653B 6.85B 5.99B 5.52B 5.11B 9.7B 9.87B 66.08B 25.92B 321B 25.71B 25.15B 1,112B | P/E 2026 |
128x | P/E 2027 * | 48.1x |
|---|---|---|---|---|---|
| Enterprise Value | 760B 7.97B 6.97B 6.42B 5.94B 11.29B 11.48B 76.88B 30.15B 374B 29.9B 29.26B 1,294B | EV / Sales 2026 |
4.1x | EV / Sales 2027 * | 3.79x |
| Free-Float |
46.2% | Yield 2026 |
0.14% | Yield 2027 * | 0.16% |
Last Transcript: Biocon Limited
| 1 day | +1.64% | ||
| 1 week | -3.50% | ||
| Current month | -3.53% | ||
| 1 month | -1.39% | ||
| 3 months | +15.37% | ||
| 6 months | +6.77% | ||
| Current year | +2.45% |
| 1 week | 394.85 |  | 431.75 |
| 1 month | 394.85 | | 432.15 |
| Current year | 337.7 | | 440.4 |
| 1 year | 331 | | 440.4 |
| 3 years | 217.5 | | 440.4 |
| 5 years | 191.55 | | 440.4 |
| 10 years | 114.82 | | 487.75 |
| Manager | Title | Age | Since |
|---|---|---|---|
Saurabh Paliwal
IRC | Investor Relations Contact | - | - |
Shreehas Tambe
CEO | Chief Executive Officer | - | 2026-03-31 |
Kedar Upadhye
DFI | Director of Finance/CFO | 48 | 2026-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 71 | 1999-12-31 | |
| Chairman | 73 | 1978-11-28 | |
| Director/Board Member | 62 | 2018-07-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.64% | -3.50% | +9.26% | +58.91% | 6.71B | |
| -0.38% | +0.40% | +71.69% | +128.83% | 56.71B | |
| +4.91% | -3.30% | +71.97% | +92.14% | 51.3B | |
| +1.48% | +10.52% | +23.01% | +495.47% | 25.26B | |
| -0.59% | -1.00% | -16.73% | -12.99% | 23.65B | |
| +3.93% | +7.11% | +44.20% | -1.96% | 18.69B | |
| +2.01% | +7.22% | +41.55% | -24.93% | 17.71B | |
| -6.84% | +4.81% | +201.88% | +348.11% | 17.7B | |
| -0.92% | +8.90% | +38.48% | - | 14.26B | |
| +1.76% | +5.82% | +31.23% | +195.70% | 14.1B | |
| Average | +0.70% | +2.60% | +51.65% | +142.14% | 24.61B | |
| Weighted average by Cap. | +1.07% | +1.96% | +57.42% | +142.68% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 170B 1.78B 1.56B 1.44B 1.33B 2.53B 2.57B 17.2B 6.75B 83.59B 6.69B 6.55B 289B | 200B 2.1B 1.83B 1.69B 1.56B 2.97B 3.02B 20.24B 7.94B 98.38B 7.87B 7.7B 341B |
| Net income | 5.22B 54.7M 47.84M 44.09M 40.78M 77.52M 78.83M 528M 207M 2.57B 205M 201M 8.88B | 13.22B 139M 121M 112M 103M 196M 200M 1.34B 525M 6.5B 520M 509M 22.51B |
| Net Debt | 107B 1.12B 978M 902M 834M 1.59B 1.61B 10.79B 4.23B 52.46B 4.2B 4.11B 182B | 105B 1.1B 959M 884M 818M 1.55B 1.58B 10.59B 4.15B 51.45B 4.12B 4.03B 178B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-09 | ₹403.55 | +1.64% | 5,590,149 |
| 26-07-08 | ₹397.05 | -2.42% | 2,984,173 |
| 26-07-07 | ₹406.90 | -4.10% | 3,261,586 |
| 26-07-06 | ₹424.30 | -0.59% | 3,802,294 |
| 26-07-03 | ₹426.80 | +1.96% | 6,403,875 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BIOCON Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
